Medpace Holdings (MEDP) is back in focus after several law firms highlighted upcoming deadlines for investors in securities class action lawsuits, keeping attention on allegations around backlog cancellations and growth expectations.

At a latest share price of US$458.69, Medpace has a 1 month share price return of 6.6% and a year to date share price return that is down 19.7%, while the 1 year total shareholder return of 56.2% points to stronger longer term momentum despite recent legal headlines and earnings related volatility.

If this kind of legal and earnings driven volatility has your attention, it can help to compare with other healthcare names using a focused screener such as 40 healthcare AI stocks.

With Medpace trading around US$458.69, screens flag a discount to one intrinsic value estimate even as legal questions and premium valuation metrics linger. Is this a genuine opportunity, or is the stock already pricing in robust growth?

Most Popular Narrative: 8.3% Undervalued

At a last close of US$458.69 versus a widely followed fair value of about US$500.08, the current price sits below that narrative anchor, which rests on detailed assumptions about Medpace's contracts, margins, and cash flows.

The rapid revenue acceleration in 2025 is heavily influenced by a therapeutic mix shift toward faster-burning studies (such as metabolic trials) with higher reimbursable costs, increasing "pass-through" revenue that is less margin-accretive, which could result in lower underlying revenue and EBITDA growth once this project mix normalizes.

Funding for many clients, especially small biotech, remains fragile, with low cancellations having driven recent upside; should the improved funding or lower cancellations reverse (as seen in previous quarters), revenue and earnings growth could sharply decelerate, indicating that the current growth levels may not be sustainable.

Want to see what keeps this valuation above the current price? The narrative leans on measured revenue growth, margin resilience, and a future earnings multiple that assumes Medpace keeps converting its pipeline efficiently. Curious which specific growth, profitability, and discount rate inputs hold that fair value together? The full narrative lays out each piece.

Result: Fair Value of $500.08 (UNDERVALUED)

However, faster burning biotech contracts and higher staffing and investigator costs could weigh on margins if productivity or backlog trends decline from here.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Multiples Point To A Richer Price Tag

The fair value narrative pegs Medpace as about 8.3% undervalued, but the current P/E of 28.5x tells a tighter story. It sits below the Global Life Sciences industry at 34.2x and well below peers at 48.5x, yet above a fair ratio of 21.4x, which hints at valuation risk if sentiment cools.

For a closer look at how this price compares with earnings power, and how that gap to the fair ratio might close over time, see the valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of valuations, legal questions, and earnings sensitivity leaves you undecided, it makes sense to review the data yourself and move quickly while sentiment is still being formed. Then weigh those potential upsides alongside the 3 key rewards

Looking for more investment ideas?

If Medpace has sharpened your focus, do not stop here. Use the tools available and line up a wider watchlist while others stay on the sidelines.

• Target potential upside in overlooked companies by scanning the screener containing 22 high quality undiscovered gems that already show solid fundamentals and room to grow.
• Strengthen your core holdings by filtering for the solid balance sheet and fundamentals stocks screener (46 results) that can better withstand shocks and keep options open for future opportunities.
• Dial back risk without stepping out of the market by reviewing 65 resilient stocks with low risk scores that screen well on stability and financial resilience.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.